Reduced FRG1 expression promotes angiogenesis via activation of the FGF2-mediated ERK/AKT pathway

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Identifying novel therapeutic targets for cancer is crucial for developing effective anti-angiogenic strategies.
• Previous research linked reduced Fragilis (FRG1) to altered mitogen-activated protein kinase (MAPK) signaling in prostate and breast cancers.

Purpose of the Study:

• To investigate the role of FRG1 in tumor angiogenesis.
• To elucidate the molecular mechanisms by which FRG1 influences tumor vascularization.

Main Methods:

• Studied the effect of FRG1 depletion on human umbilical vein endothelial cells (HUVECs) proliferation, migration, and tubule formation.
• Utilized multiple animal models to validate findings in vivo.
• Investigated the molecular pathways involving Fibroblast Growth Factor 2 (FGF2), Extracellular signal-regulated kinase (ERK), and Protein kinase B (AKT) signaling.

Main Results:

• Depleted FRG1 levels significantly enhanced HUVEC proliferation, migration, and tubule formation in a paracrine manner.
• FRG1 depletion in breast cancer cells led to increased FGF2 expression.
• This FGF2 upregulation activated the ERK/AKT signaling cascade in endothelial cells, promoting angiogenesis.
• In vivo studies confirmed the pro-angiogenic role of FRG1 depletion.

Conclusions:

• FRG1 plays a significant role in promoting tumor angiogenesis.
• FRG1 functions upstream of FGF2, influencing the ERK/AKT pathway in endothelial cells.
• Targeting FRG1 represents a promising therapeutic strategy for anti-angiogenic cancer therapy, potentially overcoming resistance mechanisms.